Good news! Like killing two birds with one stone! Pardon my brutal idiom here!
"There’s another promising GLP-1 agonist correlation: Patients with colon cancer taking GLP-1 medications (Ozempic et al.) had a 5-year mortality rate of just 15.5 percent, compared with 37.1 percent in non-users. That’s from an observational study, so causation isn’t proven, but the researchers point to several possible mechanisms, including the drugs’ dampening of systemic inflammation."
"A new University of California San Diego study offers compelling evidence that GLP-1 receptor agonists — the class of drugs behind Ozempic, Wegovy and Mounjaro, for example — may do more than regulate blood sugar and weight.
In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to those who weren’t on the drugs (15.5% vs. 37.1%). ..."
From the abstract:
"Colorectal cancer is a leading cause of morbidity and mortality worldwide. This study investigates the association between GLP-1 receptor agonists (GLP-1 RAs) and five-year mortality in patients with primary colon cancer, considering BMI.
Using data from the University of California Health Data Warehouse, 6,871 patients were analyzed.
Five-year mortality was 15.5% for GLP-1 RA users compared to 37.1% for non-users. Analyses showed significantly lower odds of five-year mortality with GLP-1 RA use (OR = 0.38, 95% CI: 0.21–0.64).
This benefit persisted after adjusting for confounders, including disease severity, but was found to only extend to high obese patients (BMI > 35) in stratified modeling."
GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients (original news release)
No comments:
Post a Comment